Bulk Inquiry
LXY18
- Soluble in 0.1N HCl(aq), DMSO and EtOH
- MF: C18H15BrN2O3
- MW: 387.23
Description
LXY18 is a potent, brain-penetrant and orally available Aurora kinase B relocation blocker with a MEC value of 3.5 nM. LXY18 prevents cytokinesis by blocking AURKB relocalization in mitosis and exhibits broad-spectrum antimitotic activity in vitro. Moreover, LXY18 is a disruptor of cell division, at sub-nanomolar concentrations.
More Information
| Parent CAS No. | 2857857-89-5 |
|---|---|
| Chemical Name | N-(3-(6-Bromoquinolin-4-yloxy)-5-methoxyphenyl)acetamide |
| Short Description | Aurora B relocation blocker |
References
- J Li et al. Orally Bioavailable 4-Phenoxy-quinoline Compound as a Potent Aurora Kinase B Relocation Blocker for Cancer Treatment. ACS Pharmacol Transl Sci. 2023 Jul 21;6(8):1155-1163.
- J Kalashova et al. The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells. PLoS One. 2023 Oct 30;18(10):e0293283.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1540 | VX 680 |
From $66.00 |
| 1541 | ZM 447439 |
From $93.50 |
| 1580 | AZD1152-HQPA |
From $77.00 |
| 1783 | AMG 900 |
From $121.00 |
| 1836 | CCT 137690 |
From $126.50 |
| 2023 | PF 03814735 |
From $132.00 |
| 2096 | Hesperadin |
From $104.50 |
| 2219 | AT 9283 |
From $99.00 |
| 2906 | SNS 314 mesylate |
From $99.00 |
| 3920 | GSK1070916 |
From $121.00 |
| 4073 | CYC-116 |
From Inquiry |
